Search

Your search keyword '"Suzuki, Tadaki"' showing total 919 results

Search Constraints

Start Over You searched for: Author "Suzuki, Tadaki" Remove constraint Author: "Suzuki, Tadaki"
919 results on '"Suzuki, Tadaki"'

Search Results

1. Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023

3. Infection-Induced SARS-CoV-2 Seroprevalence among Blood Donors, Japan, 2022

4. Macacine alphaherpesvirus 1 (B Virus) Infection in Humans, Japan, 2019

7. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

10. Identification of SARS-CoV-2 Mpro inhibitors containing P1’ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2

14. COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study)

15. Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in a COVID-19 hamster model

17. Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan

18. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents

21. Author Correction: Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice

22. Serum anti-nucleocapsid antibody level induced after primary infection is an immunological surrogate of protection against SARS-CoV-2 re-infection in hybrid immunity holders

25. Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval

28. High titers of infectious SARS-CoV-2 in corpses of patients with COVID-19

29. Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults

30. Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization

31. Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant-Infected Vaccinees

33. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2

34. Characterization of a new SARS-CoV-2 variant that emerged in Brazil

37. Changes in SARS-CoV-2 viral load and titers over time in SARS-CoV-2-infected human corpses

38. Extraction of the CDRH3 sequence of the mouse antibody repertoire selected upon influenza virus infection by subtraction of the background antibody repertoire

40. Mpox Neutralizing Antibody Response to LC16m8 Vaccine in Healthy Adults

41. Neutrophil adhesion to vessel walls impairs pulmonary circulation in COVID-19 pathology

43. Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies

44. Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice

45. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters

46. COVID-19–Associated cardiac pathology at the postmortem evaluation: a collaborative systematic review

50. Lethal severe fever with thrombocytopenia syndrome virus infection causes systemic germinal centre failure and massive T cell apoptosis in cats

Catalog

Books, media, physical & digital resources